Golden State Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Golden State Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-64	Closed	-$1.23K	–	1754
2025 Q3	$1.23K	Hold	64	–	–	﹤0.01%	1477
2025 Q2	$1.09K	Hold	64	–	–	﹤0.01%	1425
2025 Q1	$4.08K	Sell	64 -55	-46%	-$5.79K	﹤0.01%	1211
2024 Q4	$14.5K	Buy	+119	New	+$14.6K	﹤0.01%	855
2020 Q2	–	Sell	-25	Closed	-$2K	–	838
2020 Q1	$2K	Buy	+25	New	+$2.86K	﹤0.01%	874
2019 Q4	–	Sell	-25	Closed	-$2K	–	814
2019 Q3	$2K	Hold	25	–	–	﹤0.01%	987
2019 Q2	$3K	Hold	25	–	–	﹤0.01%	950
2019 Q1	$3K	Buy	+25	New	+$3.21K	﹤0.01%	993

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Golden State Wealth Management's SRPT Position: Q4 2025 in Review

Golden State Wealth Management sold out of Sarepta Therapeutics (SRPT) in Q4 2025, closing a stake of 64 shares — an estimated $1.23K sold.

Golden State Wealth Management first reported a position in SRPT in Q1 2019 and held it in 8 quarters. The position peaked at $14.5K in Q4 2024. 347 funds tracked by Wall St. Rank hold SRPT as of Q4 2025.

Golden State Wealth Management reported no remaining Sarepta Therapeutics position as of Q4 2025 after selling out during the quarter.
Golden State Wealth Management sold 64 Sarepta Therapeutics shares in Q4 2025, an estimated $1.23K.
Golden State Wealth Management first reported a position in Sarepta Therapeutics in Q1 2019 and held it in 8 quarters.
Golden State Wealth Management's Sarepta Therapeutics position peaked at $14.5K in Q4 2024.
347 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2025.

Based on Golden State Wealth Management's 13F filing for Q4 2025, filed 13 Feb 2026.